Phase 2 Trial of Single Agent Gedatolisib (PF-05212384), a Dual PI3K/mTOR Inhibitor, for Adverse Prognosis and Relapse/Refractory AML: Clinical and Transcriptomic Results

Conclusion: Gedatolisib, a dual PI3K/mTOR inhibitor used as a single therapy had no clinical benefit in adverse prognosis and relapsed/refractory AML patients. Combination of Gedatolisib with chemotherapy was not explored, yet this could be a potential therapeutic development, as it was recently shown for Midostaurin and FLT3-mutated AML.DisclosuresNo relevant conflicts of interest to declare.

Source: Blood - November 21, 2018 Category: Hematology Authors: Vargaftig, J., Farhat, H., Ades, L., Briaux, A., Benoist, C., Turbiez, I., Vey, N., Glaisner, S., Callens, C. Tags: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation Source Type: research